# Evecxia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evecxia-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.evecxia.com/
- Total disclosed funding: $4.6M
- Latest round: Series A (Sep 15, 2025)
- Investors on record: 1

## About

Evecxia, Inc. is a biopharmaceutical company focused on developing innovative drug delivery technologies to enhance serotonin production, targeting mental health conditions with unmet treatment needs. Founded in 2013 in the United States, Evecxia, Inc. specializes in therapeutic drugs aimed at increasing serotonin levels in the brain. The company, led by CEO Jacob Jacobsen. In September 2025, Evecxia Therapeutics, Inc. raised USD 4.61 million in venture funding from new investor Collage Partners. Other unspecified investors also participated in the round. .Evecxia Therapeutics focuses on developing proprietary drug delivery technologies that leverage the therapeutic potential of 5-hydroxytryptophan (5-HTP), the natural precursor to serotonin. Their core product offerings aim to enhance serotonin production in the brain, targeting mental illnesses that are inadequately addressed by existing treatments. Evecxia's drugs are designed as adjunctive therapies for patients suffering from depression, particularly for those who do not achieve sufficient relief from standard antidepressants like SSRIs and SNRIs. The company's innovations are indicative of a shift towards more effective treatment options in mental health care, with a particular emphasis on improving patient outcomes in diverse demographics, including various age groups facing mental health challenges. Currently, Evecxia's products are being developed for distribution primarily in North America and Europe, focusing on markets where there is significant demand for enhanced mental health therapies.Evecxia Therapeutics operates on a business model centered around partnerships and direct-to-consumer engagements, facilitating access to their innovative 5-HTP-based therapeutics. Their revenue structure includes sales through healthcare providers, pharmacies, and potentially digital health platforms, catering directly to patients who require adjunctive treatments for mental health conditions. While specific pricing plans for their products are not publicly disclosed, the company’s offerings are expected to be strategically positioned within the healthcare market to ensure accessibility and affordability for end-users. Evecxia's flagship products are anticipated to generate revenue as they gain regulatory approval and enter the market, establishing a steady revenue stream from both B2B transactions with healthcare providers and direct sales to consumers in need of effective mental health solutions.Evecxia, Inc. plans to expand its product line, focusing on new therapeutics designed to enhance serotonin levels, with anticipated market entry following regulatory approvals. The company targets expansion into additional markets in Europe and North America by 2023, leveraging recent funding of USD 6.5 mn raised in June 2020 to support these initiatives and facilitate growth in areas with high demand for mental health treatments. In September 2025, Evecxia, Inc. raised USD 5 million in venture funding from new investor Collage Partners. Other unspecified investors also participated in the round. The company will use the September 2025 funding to support clinical trials and further develop treatments for OCD and depression.

## Funding rounds

- Series A, Sep 15, 2025, $4.6M — Collage Partners

## Investors

- Collage Partners (https://capitalatlas.ai/funds/collage-partners) — Series A